Agios Pharmaceuticals, Inc.

Good morning and welcome to AGO's first quarter 2020 conference call. At this time, all participants are now listening online mode. There will be a question and answer session at the end. Please be advised that this call is being recorded at AGO's request. I would now like to turn the call over to Holly Manning, Director of Investor Relations.

Thank you, Operator. Good morning, everyone, and welcome to Agios' first quarter 2020 conference call. You can access slides for today's call by going to the investor section of our website, agios.com. With me on the call today with prepared remarks are Dr. Jackie Faust, our Chief Executive Officer, Dr. Chris Bowden, our Chief Medical Officer, Darren Miles, our Senior Vice President of U.S. Commercial and Global Marketing, and Andrew Hirsch, our Chief Financial Officer and Head of Corporate Developments. Dr. Bruce Carr, our Chief Scientific Officer, will join for Q&A. Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factor section of our most recent Form 10-K filed with the SEC and any other filings that we may make with the FCC. With that, I will turn the call over to Jackie.

Thanks, Holly. Good morning, everyone, and thank you for joining our first quarter 2020 results call. At the beginning of the year, we laid out ambitious plans for 2020. Along with the rest of the world, we couldn't know what challenges would lay ahead related to the impact of the COVID-19 pandemic. The past few weeks have stretched each of us personally and professionally as we adapt to the necessary constraints of physical distancing and realize more than ever how our actions can impact the people around us. We wish continued good physical and emotional health to all of you, our patients, the system's healthcare professionals, our AGEOS team members, and humanity at large. There is no modern playbook for a crisis of this type, but at OGS we quickly realigned our priorities around the health of our employees and their families, our communities, and the patients we serve. To start, in February we activated our organizational resiliency team and clinical operations response team to assess the evolving coronavirus outbreak and put plans in place to address its impact on every facet of our business. On March 10th, we made the decision for most of our employees, including lab and field personnel, to work from home to reduce the likelihood of exposure or transmission of the virus to others, a policy that remains in effect. Our supply chain strategy has ensured uninterrupted supply of our commercial and clinical medicines, and our patient assistance program, MyAGIOS, has been a constant resource to help new and existing TIBSOVO patients remain on therapy. including those that have lost insurance due to unemployment. With the help of our dedicated employees, we have been actively supporting our communities and health care workers, including organizing a donation of AGIOS's personal protective equipment supply to local hospitals, raising more than $22,000 for the Greater Boston Food Bank, and encouraging blood donations. The teamwork and resilience I've witnessed in these last few weeks has truly been remarkable and gives me hope that we will come out of these challenging times even stronger than we were before. Turning to the impact on our business, we've taken a fresh look at our priorities and made important resource allocation decisions to support execution against the most critical objectives for our business. During this period of disruption and uncertainty, we're focused on delivering on our top objectives, including driving TIPSOVO performance, enrolling our late-stage AML and glioma studies, and advancing mid-pivot across multiple disease areas, all while conserving cash and increasing our financial flexibility. As a result of our prioritization efforts, we have extended our forecasted cash runway by six months through June of 2022. Andrew will further discuss the decisions we have made later in the call. As I mentioned earlier, we created a clinical trial task force in February to ensure the safety of patients on our clinical studies and to implement plans to keep as many patients on study as possible. We have been managing this on a patient-by-patient basis, consistent with FDA guidance. Chris will walk you through the impact of each program and trial, as well as the measures our team have taken to address pandemic-related challenges. On the commercial side, we saw strong TIPSOVO performance to start the year and an acceleration of revenues during the month of March into April, which reinforces our confidence in our 2020 product revenue guidance. Darren will discuss the trends we saw in Q1 in more detail. Through these efforts, we remain on track to achieve our AGEOS 2025 strategic vision. Before I wrap up, I want to thank every AGEOS employee for their incredible work over these last few weeks. Your determination in the face of adversity has quite literally saved lives, and I could not be prouder to be on your team. Chris, let me turn it over to you.